-
Healthgen Biotech Wonderful memories at KSSCR International Symposium 2019
On September 26-28, 2019, the 3-days KSSCR International Symposium 2019 was successfully ended in Grand Hilton Seoul, South Korea.
2019 ISSCR/KSSCR International Symposium is a joint meeting of the Korean Society for Stem Cell Research (KSSCR) and th...
Posted by
Site editor|2019-10-08
LearnMore
-
Recombinant Human Serum Albumin(OsrHSA) From Rice Was Approved By USA FDA For Clinical Study
On August 10, 2019, Wuhan Healthgen Biotechnology Co., Ltd. received approval from the FDA of the United States for clinical trials on OsrHSA injection that was produced from rice expression platform. This is the first blood product from China which was approved for clinical tr...
Posted by
Site editor|2019-08-10
LearnMore
-
Healthgen Biotech will attend the World Advanced Therapies & Regenerative Medicine Congress 2019 in London, UK
Date: 5/15/2019 - 5/17/2019
Venue: Business Design Centre
Address: Business Design Centre Ltd,, 52 Upper St, London N1 0QH
Booth No: #6
The World Advanced Therapies&Regenerative Medicine Congress is Europe’s most important advance...
Posted by
Site editor|2019-05-04
LearnMore
-
Recombinant Human Serum Albumin(OsrHSA) Derived From Oryza Sativa Has Been Approved By CFDA For The Clinical Trial In China
OsrHSA, a recombinant human serum albumin derived from transgenic rice seeds has gained the approval of the clinical trial from Chinese Food and Drug Administration (CFDA) at 28 April, 2017. It is a milestone event in the research and applications of plant bioreactor, which ...
Posted by
Site editor|2017-05-22
LearnMore
-
Healthgen Biotech's tenth anniversary celebration
In 18th Dec 2016, the innovative high-tech enterprise- Wuhan Healthgen Biotechnology Corp.(Healthgen Biotech, Securities Code: 833101) which is focusing on developing, manufacturing and marketing a serious of recombinant proteins and small peptide products in the rice g...
Posted by
Site editor|2016-12-24
LearnMore